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In the Archives January issue (1), I have read with 
interest and surprise a letter by Marashi and Nasrabadi 
concerning the use of hydroxyethyl starch (HES, hetastarch; 
best known under the registered name Plasmasteril) to treat 
severe aluminium phosphide (AlP) poisoning. 
At the current level of scientific evidence such a claim 
seems unacceptable.
Aluminium phosphide poisoning (the compound is 
commercially available as a fumigant for stored cereals) is 
believed to be caused by phosphine (PH3), as it induces 
mitochondrial damage and severe multi-organ failure (2). 
The poisoning is mostly reported from the Indian 
subcontinent, and is largely unknown in Europe. The 
management is exclusively supportive (gastric lavage with 
KMnO4 solution, treatment of shock, lactic acidosis, etc.), 
since there is no specific antidote (2, 3). Some traditional 
(e.g. coconut oil) or “modern” interventions (e.g. 
haemodialysis) have not been adequately assessed, and rest 
instead on pathophysiological assumptions, anecdotal 
reports, and wishful thinking (2, 3).
Lactic acidosis type A, a form of high anion gap 
metabolic acidosis, is just one of the many aspects of AlP 
poisoning with fatal prognosis. Treatment with NaHCO3 in 
this situation is highly controversial, as the authors (1) 
appropriately underscore. However, the suggested 
administration of colloid solutions is potentially even more 
dangerous. The authors corroborate their proposal by 
quoting just one hypothetic paper of their own on the role 
of HES in acute AlP poisoning (4) with no further 
experimental evidence. It is not clear whether they are 
advocating starch solution administration at arterial pH >7 
(as stated in the letter) or <7, or what the dosage of 500-
1000 mL of HES really means (i.e. isotonic, 6 g L-1, or 
hypertonic, 9 g L-1 solution)?
Contrary to their claim (1), colloidal solutions such as 
dextrans, pentastarch, polygeline, and HES in particular 
may worsen metabolic acidosis and shock, possibly due to 
the substance’s deposition in the tissue and its interaction 
with fibrinogen, leading to even more severe coagulopathy 
and organ failure (5). Crystalloid solutions are better 
tolerated and equally effective plasma expanders (6).
Beware of ill-founded therapeutic enthusiasm!
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